Search Results

Ipsen bolsters rare disease portfolio with acquisition of liver disease specialist Albireo.

Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.

Albireo Pharma, Inc. announced the grant to its newly appointed Chief Medical Officer, Paul D. Streck, M.D., of inducement restricted stock units to acquire 63,966 shares of Albireo’s common stock.

Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions.

Albireo Pharma, Inc. today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced the grant of inducement restricted stock units to acquire 13,700 shares of Albireo’s common stock.

Albireo Pharma, Inc. announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022.

Ipsen S.A. announced that Anemone Acquisition Corp., its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Albireo Pharma, Inc. at a price of $42.00 per share.

Albireo Pharma, Inc., a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced the grant of inducement restricted stock units to acquire 13,700 shares of Albireo’s common stock.

Albireo Pharma, Inc. (Nasdaq: ALBO) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) and issued a Prescription Drug User Fee Act (PDUFA) action date of June 15, 2023 for a second Bylvay (odevixibat) indication for patients with Alagille syndrome (ALGS)